Medical/Pharmaceuticals
Kintor Pharma Announces Completion of Patient Enrollment in Phase II Clinical Trial of GT20029 for Treatment of Androgenetic Alopecia in China
SUZHOU, China, Aug. 22, 2023 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecules and biological therapeutics, announced that the company has completed the enrollment of 180 patients for the Phase...
2023-08-22 17:13
1559
Introducing NeoMab™: GemPharmatech's Innovative Antibody Gene Humanized Mouse Model
SAN DIEGO, Aug. 21, 2023 /PRNewswire/ -- GemPharmatech is proud to announce the launch of NeoMab™, our independently developed fully antibody gene humanized mouse model, after four years of rigorous research and validation. NeoMab™ is specifically designed to meet the burgeoning therapeutic antib...
2023-08-22 08:59
1471
Lunit Backs the Potential of Tertiary Lymphoid Structures Analysis as an Emerging Biomarker for Lung Cancer Treatment - to be presented at WCLC 2023
- A collaborative study demonstrates that AI analysis of Tertiary Lymphoid Structures (TLS) in tumors can predict treatment response in non-small cell lung cancer patients SEOUL, South Korea, Aug. 21, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for canc...
2023-08-21 21:00
2095
CanariaBio Achieves Significant Milestone with FDA's Orphan Drug Designation for MAb-AR20.5 Targeting Pancreatic Cancer
The investigational monoclonal antibody becomes the first to target Mucin 1 (MUC1) and receive this designation. PYEONGTAEK, South Korea, Aug. 21, 2023 /PRNewswire/ -- CanariaBio Inc., a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative immun...
2023-08-21 20:00
1816
Zepp Health Corporation Reports Second Quarter 2023 Unaudited Financial Results
AMSTERDAM, Aug. 21, 2023 /PRNewswire/ -- Zepp Health Corporation ("Zepp" or the "Company") (NYSE: ZEPP) today reported revenues ofRMB0.65 billion (US$89.4 million); a basic and diluted net loss per share of RMB0.29 (US$0.04); and a basic and diluted net loss per ADS ofRMB1.15 (US$0.16) for the se...
2023-08-21 18:15
2405
So-Young Reports Unaudited Second Quarter 2023 Financial Results
BEIJING, Aug. 21, 2023 /PRNewswire/ -- So-Young International Inc. (Nasdaq: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced its unaudited financial resul...
2023-08-21 17:30
2859
TradeUP Acquisition Corp. Announces Extension of the Deadline for an Initial Business Combination
NEW YORK, Aug. 18, 2023 /PRNewswire/ -- TradeUP Acquisition Corp. (the "Company" or "TradeUP") (NASDAQ: UPTD) today announced that, in order to extend the date by which the Company must complete its initial business combination fromAugust 19, 2023 to September 19, 2023, for each public share that...
2023-08-19 04:30
5207
Akeso Announced First Patient Dosed in Phase 3 Trial of Ivonescimab versus Tislelizumab for First-line Treatment of Squamous NSCLC
HONG KONG, Aug. 18, 2023 /PRNewswire/ -- Akeso Inc. ("Akeso", 9926. HK) announced today that the first patient has been dosed in a head-to-head phase III trial of ivonescimab, a potential first-in-class investigational PD-1/VEGF bi-specific antibody discovered by Akeso. The Phase III trial will e...
2023-08-18 20:00
6141
Inmagene's anti-OX40 mAb demonstrated an extended half-life and a favorable safety profile in a Phase I study
* IMG-007 has the potential to provide Q12W or less frequent dosing based on an extended half-life * IMG-007 has demonstrated a favorable safety profile, consistent with a silenced ADCC function via bioengineering * IMG-007 is being evaluated in two global proof-of-concept trials SAN DIEGO,...
2023-08-18 19:00
4693
Nature-inspired pressure sensing technology aims to transform healthcare and surgical robots
NUS researchers take a leaf out of nature's book to develop 'eAir' — an
aero-elastic sensor that revolutionises the way pressure is detected
SINGAPORE, Aug. 18, 2023 /PRNewswire/ -- Researchers at the National
University of Singapore
2023-08-18 17:54
1722
United Imaging Healthcare delivers its 2023 Half-Year report, with revenue growth of 26.35% in the first half of 2023
SHANGHAI, Aug. 18, 2023 /PRNewswire/ -- United Imaging Healthcare (SSE:688271), a global innovator in cutting-edge medical imaging and radiotherapy equipment, has unveiled its highly anticipated 2023 half-year report, revealing robust growth. The report indicates that the company achieved5.27 bil...
2023-08-18 17:29
2640
JinMed (NASDAQ: ZJYL) Rings the Nasdaq Stock Market Closing Bell on August 17
CHANGZHOU, China, Aug. 17, 2023 /PRNewswire/ -- Jin Medical International Limited ("the Company" or "JinMed") (NASDAQ: ZJYL), the world's leading provider of rehabilitation equipment, rang the bell at the New York Stock Exchange by its Chairman and CEOWang Erqi on August 17, to celebrate the Com...
2023-08-18 11:36
4194
Thrombotic AEs of Hemlibra (emicizumab) were 2.8 times more frequent than those of FVIII replacements.
* Analyzed the FDA FAERS data…to compare the thrombotic AEs of Hemlibra vs. FVIII replacements. YONGIN, South Korea, Aug. 17, 2023 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced on August 17, 2023 that it has presented the results of analyzing and...
2023-08-18 08:58
2281
The Global Medical Robotics Conference 2023: A Deep Dive into China's Booming Surgical Robotics Landscape
BEIJING, Aug. 17, 2023 /PRNewswire/ -- The groundbreaking Global Medical Robotics Conference 2023 will be held inBeijing on September 8, 2023. This unprecedented event brings together a wide range of surgical robotics from around the world, making it the first of its kind globally. The conference...
2023-08-18 02:08
1716
Neurophth Announces First Patient Dosed in Phase I/II Clinical Trial of Second Gene Therapy
WUHAN, China and SAN DIEGO, Aug. 17, 2023 /PRNewswire/ -- Neurophth Therapeutics, Inc. ("Neurophth") announced today that the first patient has been dosed in the international multi-region, multi-center Phase I/II clinical trial for the treatment of Leber hereditary optic neuropathy caused byND1 ...
2023-08-17 21:00
1450
Minghui Pharmaceutical Inc. Announces First Patient Enrollment in the Phase 3 Clinical Study of MH004 Cream for Treatment of Mild to Moderate Atopic Dermatitis
SHANGHAI, HANGZHOU, China and WILMINGTON, Del., Aug. 17, 2023 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a leading clinical-stage biopharmaceutical company, today announced the successful enrollment of the first patient in the phase 3 clinical study for MH004 Cream targeting mild to moderate a...
2023-08-17 19:00
4472
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates
* Significant progress made year-to-date on key clinical assets: ‐ Uliledlimab (CD73 antibody): Encouraging early results were presented at ASCO 2023 ‐ Givastomig (Claudin 18.2 x 4-1BB bispecific antibody): Topline Phase 1 data with promising early efficacy signals, including pat...
2023-08-17 18:00
4359
2023WCLC Oral Presentation | Molecular Analysis Validates the Effectiveness of Tumor Tissue-Based and Plasma ctDNA Testing in Identifying NSCLC Patients with EGFR Exon20ins Eligible for Treatment with Sunvozertinib
* A high concordance was observed between tumor tissue-based and plasma circulating tumor DNA (ctDNA) testing in detecting EGFR exon 20 insertion (Exon20ins) mutations. * Both tumor tissue-based and plasma ctDNA testing can be used to identify patients who may benefit from treatment with su...
2023-08-17 17:10
2207
YS Biopharma Announces Unaudited Financial Results for the First Quarter of Fiscal Year 2024
Pipeline makes progress towards commercialization as robust demand for YSJA rabies vaccine continues Gross margin increases to 80.3%; balance sheet remains strong GAITHERSBURG, Md., Aug. 15, 2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biop...
2023-08-16 05:00
3198
CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency
The MOU signed by CytoMed and Hangzhou CNK Therapeutics Co., Ltd is the first
of several collaborative efforts inNorth Asia.
SINGAPORE, Aug. 15, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited
2023-08-16 01:00
2232
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
6801
